Description
BPC-157 is a synthetic fifteen-amino-acid peptide corresponding to a partial sequence of body protection compound, a protein identified in human gastric juice. It has one of the largest preclinical literatures of any peptide in this category.
What you are buying
A single 5 mg vial of lyophilised BPC-157 from batch VL-2607-B, analysed by Northlake Analytical, LLC before release. The full certificate of analysis is published on this site, including identity confirmation by LC-MS, purity by RP-HPLC at 214 nm, water content, acetate content and bacterial endotoxin.
The batch number printed on the vial matches the certificate. If they ever do not, tell us and we will withdraw the batch.
Research context
Published work on BPC-157 is overwhelmingly preclinical, using rodent models of induced injury — tendon and ligament transection, muscle crush, and chemically induced gastrointestinal lesions among them. Proposed mechanisms in the literature centre on angiogenic signalling and interaction with the nitric oxide pathway.
There is no established human efficacy evidence base for BPC-157, and it is not an approved drug. Our research overview covers the literature and the current regulatory position in detail, including its Category 2 placement in the FDA’s review of bulk drug substances for compounding.
Handling
Supplied lyophilised and stable in that form at −20 °C. Allow the vial to reach room temperature before opening. Reconstitution, stock concentration and aliquoting are covered in the storage and reconstitution guide.
Note that vial mass is not peptide mass — water and acetate account for a measurable fraction, and both are published on the certificate so you can correct for them.
